National Donor Deferral Registry (NDDR) Helps Ensure That Deferred Donors Cannot Donate Their Plasma Again
The National Donor Deferral Registry (NDDR) is a database of permanently deferred plasma donors in North America. It is one of many voluntary, self-regulating initiatives taken by the source plasma collection industry and is an important component of the industry-driven safety measures taken to help ensure the safety of the final therapies.
All donors who test "reactive" for the viral agents for HIV, HBV and HCV are added to the NDDR and are permanently prohibited from donating source plasma at participating licensed and industry-certified centers in the U.S. and Canada.
The NDDR first was made available to all blood and source plasma facilities in December 1993. Haemonetics, a valued partner of PPTA, is responsible for the administration and customer support services of the NDDR.
All inquires should be directed to the NDDR Customer Support Desk at 1-877-534-3578.
Zika Virus and Plasma Protein Therapies +
Recent scientific and public press reports have heightened awareness of the Zika virus and its emergence in the Americas (1). The temporal link between the emergence of the virus in Brazil and the birth of babies with microcephaly (2) is most alarming. PPTA is aware that persons who rely on plasma protein therapies are understandably concerned whether these therapies are safe with respect to the Zika virus.
David Bell Elected Chair of PPTA Global Board of Directors +
The Plasma Protein Therapeutics Association (PPTA) Global Board of Directors elected Mr. David Ian Bell as the new Chairman, effective January 2016. Mr. Bell will serve as Chairman for a term of three years.Read More
IQPP Standards Public Comment Period Now Open +
In accordance with the procedures for developing PPTA Voluntary Standards, the following documents are hereby issued for public review, from January 22, 2016 – March 21, 2016.Read More
PPTA Standards Programs